Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 dichloride in castration-resistant prostate cancer with bone metastases
2012-000075-16Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2012
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3 trial of radium-223 dichloride in prostate cancer (PCa), sponsored by Bayer. Primary endpoints: Acute safety, Long-term safety and 1 more. Started Mar 2012; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2012-000075-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000075-16.